EQ · XBRL financial data

Equillium financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (EQ's year ends in late March)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Mar 31, 2026
Revenue from contracts with customers	—	—	15,759	36,084	41,095	—
Research and development	19,384	26,379	37,547	37,039	—	—
General and administrative	10,164	11,407	17,239	13,567	11,936	—
Total operating expenses	29,548	37,786	77,835	50,606	49,364	—
Operating income (loss)	(29,548)	(37,786)	(62,076)	(14,522)	(8,269)	—
Interest income	476	57	420	2,334	1,381	—
Interest expense	1,099	1,073	1,053	491	—	—
Other income (expense)	358	(250)	281	(76)	—	—
Income tax expense (benefit)	0	0	0	580	361	—
Net income (loss)	(29,813)	(39,052)	(62,428)	(13,335)	(8,067)	—
Earnings per share, basic USD per share	—	(1.36)	(1.85)	(0.38)	(0.23)	—
Earnings per share, diluted USD per share	—	(1.36)	(1.85)	(0.38)	(0.23)	—
Weighted average shares, basic thousands of shares	—	28,806	33,728	34,726	35,358	—
Weighted average shares, diluted thousands of shares	—	28,806	33,728	34,726	35,358	—

Fiscal years (EQ's year ends in late March)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Mar 31, 2026
Cash and cash equivalents	23,982	50,366	59,107	23,216	18,085	61,322
Marketable securities	58,181	30,345	11,916	17,650	4,490	—
Accounts receivable	—	0	2,838	3,735	0	—
Prepaid and other current assets	3,011	2,659	2,874	4,748	2,403	953
Total current assets	85,174	83,370	76,735	49,349	24,978	62,275
Property and equipment, net	239	237	391	315	262	214
Right-of-use asset	—	1,645	1,191	796	364	567
Total assets	85,428	85,405	78,421	50,530	25,604	63,083
Accounts payable	2,766	1,225	3,977	4,707	2,676	1,295
Accrued liabilities	2,813	5,886	7,239	6,697	3,483	1,609
Current portion of long-term debt	1,666	1,428	5,714	—	—	—
Total current liabilities	7,245	8,915	32,038	27,573	6,356	3,345
Long-term debt	8,275	8,750	3,239	—	—	—
Lease liability, non-current	—	1,235	824	384	187	251
Total liabilities	15,574	18,900	46,479	27,957	6,543	3,596
Accumulated deficit	(70,925)	(109,977)	(172,405)	(185,740)	(193,807)	(221,516)
Total stockholders' equity	69,854	66,505	31,942	22,573	19,061	59,487
Total liabilities and equity	85,428	85,405	78,421	50,530	25,604	63,083
Common shares outstanding (cover page) thousands of shares	29,040	34,276	34,414	35,255	35,610	63,227

Fiscal years (EQ's year ends in late March)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Mar 31, 2026
Net income (loss)	(29,813)	(39,052)	(62,428)	(13,335)	(8,067)	—
Stock-based compensation	3,817	4,410	4,841	3,997	3,750	—
Net cash from operating activities	(24,624)	(32,081)	(8,733)	(21,783)	(19,026)	—
Purchases of property and equipment	202	57	279	50	85	—
Net cash from investing activities	(18,592)	27,406	18,684	(4,762)	13,814	—
Share repurchases	—	—	—	260	—	—
Net cash from financing activities	53,945	31,061	(1,215)	(9,228)	164	—
Net change in cash	10,763	26,384	8,741	(35,891)	(5,131)	—

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.
A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Equillium	57,164	not reported	(4,107)*	63.4M	13.9 quarters	Q2 FY26 10-QJun 30, 2026
Zeo ScientifiX	2,265	not reported	not reported	7.8M	—	Q4 FY26 10-KTJun 30, 2026
Sunshine Biopharma	13,748	9,264	(918)*	3.9M	15.0 quarters	Q2 FY26 10-QJun 30, 2026
Neuphoria Therapeutics	19,866	year only	1,214*	5.4M	—	Q4 FY26 10-KJun 30, 2026
CV Sciences	266	2,985	20*	225.8M	—	Q2 FY26 10-QJun 30, 2026
Minerva Neurosciences	24,652	not reported	(13,345)*	47.7M	5.6 quarters	Q2 FY26 10-QJun 30, 2026
Bolt Biotherapeutics	12,860	5	(6,540)*	1.9M	2.7 quarters	Q2 FY26 10-QJun 30, 2026
Intensity Therapeutics	9,529	not reported	(2,340)*	3.3M	4.1 quarters	Q2 FY26 10-QJun 30, 2026
Genprex	15,154	not reported	(5,139)*	819,709	2.9 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.